

CORRECTION

Open Access



Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study

Hiroji Uemura¹, Yosuke Koroki^{2*}, Yuki Iwaki³, Keiichiro Imanaka⁴, Takeshi Kambara⁵, Angela Lopez-Gitlitz⁶, Andressa Smith⁶ and Hirotsumu Uemura⁷

Correction to: *BMC Urol* (2020) 20:139

<https://doi.org/10.1186/s12894-020-00689-0>

In the original publication of this article [1] there were several errors in Table 1 related to the values for Disease status (nmCRPC and mCSPC).

In this correction article the correct and incorrect values are shown.

Table 1 The correct and incorrect values

Incorrect				Correct					
Disease status, n				Disease status, n					
nmCRPC	55	–	–	55	nmCRPC	34	–	–	34
mCSPC	–	51	–	51	mCSPC	–	28	–	28

Furthermore, the **Time-to-event analyses** section has several errors with the decimal values/rounding of

numbers, the incorrect and correct information is shown below

Incorrect	Correct
66 days	66.0 days
45 days	45.0 days
52 days	52.0 days
38 days	38.0 days
82 days	82.0 days
In the global population of the SPARTAN study, skin rash of any grade resolved for 81% of the patients within 59.5 days, while the median time to resolution of skin rash of any grade in the TITAN study was 100 days (Supplementary Table 2)	In the global population of the SPARTAN study, skin rash of any grade resolved for 80.6% of the patients within 59.5 days, while the median time to resolution of skin rash of any grade in the TITAN study was 100.0 days (Supplementary Table 2)
100 days	100.0 days
35 days	35.0 days
37 days	37.0 days
66 days	66.0 days

Further errors were detected, specifically under the section **Management of Rash**. This Correction article shows the incorrect and correct sentences. It was highlighted

The original article can be found online at <https://doi.org/10.1186/s12894-020-00689-0>.

*Correspondence: ykoroki@its.jnj.com

² Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 3 Rash management Target population: Safety

	SPARTAN	TITAN	PCR1008	Total
Number of safety analysis set	34	28	6	68
Rash	19 (55.88)	14 (50.00)	2 (33.33)	35 (51.47)
Patients who received supportive care for rash				
Oral antihistamine	11 (57.89)	6 (42.86)	1 (50.00)	18 (51.43)
Systemic corticosteroid	0 (0.00)	3 (21.43)	0 (0.00)	3 (8.57)
Topical corticosteroid	13 (68.42)	13 (92.86)	1 (50.00)	27 (77.14)
Drug interruption	11 (57.89)	6 (42.86)	1 (50.00)	18 (51.43)
Dose reduction	4 (21.05)	3 (21.43)	0 (0.00)	7 (20.00)
Drug discontinuation	3 (15.79)	2 (14.29)	0 (0.00)	5 (14.29)
Other	2 (10.53)	1 (7.14)	0 (0.00)	3 (8.57)

that some of the values on Table 3 were also incorrect. This Correction article shows the correct Table 3. The original article has been updated.

Incorrect:

Oral antihistamine was the most common (25/35 [71.4%]), followed by systemic and topical corticosteroids (18/35 [51.4%] and 15/35 [42.9%], respectively) (Table 3).

Correct:

Topical corticosteroid was the most common (27/35 [77.1%]), followed by oral antihistamine and systemic corticosteroid (18/35 [51.4%] and 3/35 [8.6%], respectively) (Table 3).

In the Discussion section:

Incorrect:

This could be attributed to the more frequent use of oral antihistamines (71.4%) and systemic corticosteroids

(51.4%) as supportive medication among Japanese patients when compared with patients in the global studies (combined data from SPARTAN and TITAN: antihistamines, 36.5%; systemic corticosteroids, 18.5%).

Correct:

This could be attributed to the more frequent use of topical corticosteroids (77.1%) and oral antihistamines (51.4%) as supportive medication among Japanese patients when compared with patients in the global studies (combined data from SPARTAN and TITAN: topical corticosteroids, 37.8%; antihistamines, 36.3%).

Author details

¹ Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. ² Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan. ³ Clinical Pharmacology, Janssen Pharmaceutical K.K., Tokyo, Japan. ⁴ Clinical Science, Janssen Pharmaceutical K.K., Tokyo, Japan. ⁵ Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan. ⁶ Janssen Global Research & Development, Spring House, PA, USA. ⁷ Department of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.

Published online: 22 October 2020

Reference

1. Uemura H, Koroki Y, Iwaki Y, et al. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. *BMC Urol.* 2020;20:139. <https://doi.org/10.1186/s12894-020-00689-0>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

